Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6488611 | 0.89 | TACR1 (0.80) | TACR1 | |
| SCHEMBL6479119 | 0.87 | TACR1 (0.94) | TACR1 | |
| SCHEMBL6492431 | 0.87 | TACR1 (0.77) | TACR1 | |
| SCHEMBL6478537 | 0.86 | TACR1 (1.00) | TACR1 | |
| SCHEMBL6491383 | 0.86 | TACR1 (0.83) | TACR1 | |
| SCHEMBL6479339 | 0.86 | TACR1 (1.00) | TACR1 | |
| SCHEMBL6478415 | 0.86 | TACR1 (1.00) | TACR1 | |
| SCHEMBL6480085 | 0.85 | TACR1 (0.98) | TACR1 | |
| SCHEMBL6478355 | 0.85 | TACR1 (0.75) | TACR1 | |
| SCHEMBL6479346 | 0.85 | TACR1 (0.79) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6916797-B2 | α-arylethylpiperazine derivatives as neurokinin antagonists | UCB, S.A. (BE) | 2005-07-12 | — | — | US | disclosed |
| US-20030220323-A1 | Alpha-arylethylpiperazine derivatives as neurokinin antagonists | UCB, S.A. (BE) | 2003-11-27 | — | — | US | disclosed |
| EP-1110958-A1 | Alpha-arylethylpiperazine derivatives as neurokinin antagonists | UCB, S.A. (BE) | 2001-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220323-A1 | Alpha-arylethylpiperazine derivatives as neurokinin antagonists | TACR1, TACR2, NPSR1 | TACR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.